India’s health regulatory body, the Central Drugs Standard Control Organisation (CDSCO), has issued an urgent order for all states and Union Territories to halt the production, sale, and distribution of 35 fixed-dose combination (FDC) drugs that have not been approved for use. This crackdown affects a range of medicines, including painkillers, anti-diabetic drugs, hypertension medications, neuropathic pain relievers, fertility treatments, and nutritional supplements. These drugs contain multiple components in a single pill without a valid scientific basis, posing potential risks to patient safety.
Lack of Scientific Rationale Behind Drug Combinations
The CDSCO’s directive comes after the discovery that these FDC drugs had been licensed for manufacture and distribution without proper safety and efficacy assessments. The Drugs Controller General of India (DCGI) addressed a letter to the drug controllers of all states and UTs, urging them to reassess their approval processes for such medicines. The unapproved FDCs were originally granted licenses by state authorities, but their safety and efficacy were not reviewed by the CDSCO as required by law.
In its communication, the DCGI emphasized that these drugs lacked the scientific validation necessary to ensure patient safety. Without thorough testing, there is a risk of adverse drug reactions, drug interactions, and other health hazards. As a result, the CDSCO is demanding an immediate halt to the manufacture and sale of these drugs while the investigation continues.
Uneven Enforcement of Regulations
The issue arose due to inconsistent enforcement of rules across different states. Various state authorities had granted licenses for these FDCs without adhering to the same standards, leading to confusion among pharmaceutical companies. Some manufacturers argued that they had not violated any rules because they had obtained proper licenses from state-level drug licensing authorities. However, the CDSCO has now clarified that this practice bypassed necessary safety checks, and these licenses are now being reconsidered.
The letter issued by the DCGI underlined the serious health risks posed by the unapproved FDCs. In light of the situation, the CDSCO has instructed all state and UT drug regulators to review their approval processes for FDCs, ensuring strict compliance with the provisions of the Drugs and Cosmetics Act 1940. This step is aimed at addressing the gaps in regulatory oversight and ensuring better safety standards for public health.
